Year in Review

Microbicides Advance in Development, PrEP Goes Mainstream, Modeling Illustrates the Potential of HIV Vaccines

The International AIDS Vaccine Initiative advocates a comprehensive response to the AIDS pandemic that expands existing HIV prevention, treatment and care and supports the swift development and rollout of new preventive tools and strategies. These include vaccines, treatment as a means of prevention, preexposure prophylaxis (PrEP) with antiretroviral drugs and microbicides. In 2012, we worked with our partners to conduct several preclinical studies and Phase I trials in multiple countries, built a stronger case for AIDS vaccine development through our international networks, shared our findings from ongoing research at medical conferences, expanded our network of academic and private sector partners and continued building research capacity in countries hardest hit by the AIDS pandemic.

Highlights in HIV Prevention in General and for IAVI and its Partners Specifically

Discoveries made in the field of HIV vaccine research set the stage for potentially dramatic progress toward the design of broadly effective AIDS vaccines and other preventive tools. Researchers also made preparations for a number of landmark trials starting in 2013.

HIV Prevention in 2012: The Field

IAVI and Partners in 2012

© International AIDS Vaccine Initiative, 125 Broad Street, 9th Floor New York, NY 10004 USA
T +1.212.847.1055 :: F +1.212.847.1112 :: www.iavi.org